Reordering the pecking order: management describes the company winning on a stage where it used to be too small to play
The model's full reasoning — Q3 2018 call → NOWe need answer YES or NO. Need analyze transcript. Question: Does management describe that company is NOW COMPETING AND WINNING AT A LEVEL OF MARKET THAT USED TO BE ABOVE IT? Need evidence. Transcript: Surmodics, medical device coatings, IVD. They have SurVeil DCB agreement with Abbott for worldwide commercialization rights. They will supply to Abbott, collaborate. This is a partnership with large company. Is that "competing and winning at level above it"? They got Abbott as partner for their product. Also they mention "we continue to have active and ongoing strategic in this product for multiple parties who are conducting their own clinical evaluation." They are seeking partners. They have products cleared and being evaluated by interested parties. But does management convey change in tier? They say "We are on track to become a leading and enduring medical device innovator" - future. They mention "our goals of generating consistent double-digit top-line growth by end of calendar 2019 and EBITDA margins..." Not exactly. Need see if management describes that company has recently begun to be treated as legitimate contender in situations against bigger players, and already produced results. The Abbott deal: They signed agreement with Abbott for worldwide commercialization rights for SurVeil. That is a major partnership. Is that "competing and winning at level above it"? They are supplying to Abbott, not competing. They are partnering with large player. But question asks "competing and winning at a level of market that used to be above it" - e.g., being selected by major partner? The transcript: "As many of you will recall, in late February we announced an agreement with Abbott for worldwide commercialization rights for SurVeil Drug-Coated Balloon. As part of the agreement, we will supply the SurVeil Drug-Coated Balloon to Abbott and collaborate with Abbott on product development, clinical trials and regulatory activities to obtain marketing approval in the U.S. and outside of the U.S. including Europe. Separately, Abbott also received options negotiate agreements our below the knee and AV fistula drug-coated balloon program..." This is a partnership with Abbott, a major player. Does that indicate company's standing moved up a tier? Possibly. But is it "competing and winning" against rivals? They are not competing; they are partnering.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
PRIM · Q2 2018 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing exactly this tier shift in the T&D segment: after the Willbros acquisition, the group “has been able to sign new awards with customers that have been hesitant because of previous concerns about their financial viability” and has received work from “some of the largest electrical utilities in the country.” David King notes that the work “outpaces anything he has seen in his 40-plus years,” and Pete Moerbeek adds that the one-year MSA revenue alone is now $1.1 million. Management presents these wins as a direct result of Primoris’s financial strength and parent-company backing, which previously excluded the T&D business from the largest accounts. The commentary frames the development as newly enabled and still early (only one month of T&D performance), satisfying all three required elements: a clear change in competitive tier, real business already won, and contribution still incremental relative to the company’s prior scale.
SANG · Q2 2024 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing a shift to competing at a higher tier with sophisticated mid-market clients through bundled offerings, illustrated by a recent win with a statewide park department that larger vendors couldn't serve affordably. They explicitly note this represents a change in tier ("the type of client the bundled capabilities of Sangoma can reach ... Sangoma is well positioned to play in both the small market and more sophisticated mid-market") and that it has already produced real results ("this recent win"), while conveying it is early ("there'll be a lag before it delivers material results.
WD · Q2 2022 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management explicitly describing a tier shift: from competing "predominantly with the likes of JPMorgan and Wells Fargo" to "going head-to-head with CBRE and JLL," enabled by technology investments that now allow them to "successfully compete against these much larger firms.